This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Mulling Arena Pharma's Future With Obesity Drug on Approval Path

SAN DIEGO ( TheStreet) -- Thoughts, questions and reflections on Arena Pharmaceuticals (ARNA - Get Report) following Thursday's FDA advisory panel, which voted 18-4 (with one abstention) to recommend the approval of lorcaserin for weight loss.

Congratulations, Arena. Well done. The company and its outside advisors did an excellent job presenting lorcaserin data to the panel. Not every argument the company made was necessarily persuasive, but it had data to back up its side. Most importantly, Arena was able to respond well to the questions and concerns raised by the experts on the panel about lorcaserin's safety -- rat tumors and cardiovascular risk, in particular.

Thinking back through the live blog of Thursday's panel, I can't recall any instance where Arena was dumbstruck or intimidated by the panelists' questions. Being well prepared is a big part of emerging from the FDA panel meat grinder with a positive outcome.

Which brings me to the acknowledgment that I was wrong about Arena. Going into Thursday, I was confident that the FDA panel would not recommend lorcaserin's approval mainly because the drug's efficacy is mediocre and the safety concerns insurmountable. That position was wrong, as both the FDA's internal review of lorcaserin posted last Tuesday and Thursday's 18-4 panel vote clearly demonstrated.

Arena does have an approvable weight-loss drug in lorcaserin, but when?

FDA final approval could come as early as June 27, the agency's official decision date. If FDA approves lorcaserin on that date, the drug will beat Vivus' (VVUS - Get Report) Qnexa as the first new weight-loss drug to reach the market in a decade. [Vivus' FDA decision date is three weeks later on July 17.]

Don't be surprised, however, if FDA delays the lorcaserin decision by three months to Sept. 27 to give the agency and the company more time to hash out a risk management plan and final label for lorcaserin. FDA did the same thing to Vivus, which signaled the agency was willing to approve Qnexa. Vivus's stock price has traded up since the delay was announced in early April.

If FDA pushes back the lorcaserin decision by three months to complete labeling and risk management plan discussions, it should be viewed positively for Arena.

Delay or not, Arena looks to have an approvable weight-loss drug, but that doesn't mean lorcaserin skates through without issues. [None of the late-stage obesity drugs -- lorcaserin, Qnexa or <b>Orexigen Therapeutics'</b> <span class=" TICKERFLAT">(<a href="/quote/OREX.html">OREX</a> - <a href=";ticker=OREX">Get Report</a><a class=" arrow" href="/quote/OREX.html"><span class=" tickerChange" id="story_OREX"></span></a>)</span> Contrave -- are pristine.]
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ARNA $1.52 0.00%
OREX $1.64 0.00%
VVUS $1.02 0.00%
AAPL $93.99 0.00%
FB $102.01 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs